5 completed, 4 recruiting, 1 active not recruiting. 10 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 5, Recruiting 4, Active not recruiting 1 |
| Phase 2 | 4 | Recruiting 4 |
Follow Myeloma: new trials by email Literature Review of Myeloma trials Research Report on Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) Trimethoprim / Sulfamethoxazole, Immune Globulin Intravenous - Myeloma, Non Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-07 | 2025-10-07 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) Intravenous immunoglobulin, Trimethoprim / Sulfamethoxazole, Amoxicillin clavulanic acid - Myeloma, Non-Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-06 | 2025-10-07 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) Trimethoprim Sulfamethoxazole, Amoxycillin/clavulanic acid, Immune Globulin Intravenous - Myeloma, Leukemia | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-06 | 2025-10-07 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) Immune Globulin Intravenous - Myeloma, Non Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-04-28 | 2025-10-07 |
| Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). Isatuximab, Lenalidomide, Bortezomib - Multiple Myeloma, Myeloma | Phase 3 | Active not recruiting | Poitiers University Hospital | 270 | 2021-07-17 | 2026-02-10 |
| Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs Apixaban - Myeloma, Venous Thromboembolism | Phase 3 | Completed | University Hospital, Grenoble | 108 | 2014-06-05 | 2025-08-13 |
| A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Busulfan, Melphalan, Questionnaire - Myeloma | Phase 3 | Completed | M.D. Anderson Cancer Center | 205 | 2011-09-30 | 2020-04-21 |
| Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years Lenalidomide, Bortezomib - Myeloma | Phase 3 | Completed | University Hospital, Toulouse | 700 | 2010-10-01 | 2026-04-06 |
| Maintenance Therapy Using Lenalidomide in Myeloma lenalidomide, placebo - Myeloma | Phase 3 | Completed | University Hospital, Toulouse | 614 | 2006-06-01 | 2026-04-06 |
| Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD) - Multiple Myeloma, Myeloma | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 198 | 2000-10-01 | 2011-06-10 |
Neoplasms, Plasma Cell (10) · Infections (4) · Leukemia (4) · Lymphoma (4) · Neoplasms (4) · Multiple Myeloma (3) · Disease Progression (1) · Lymphoma, Non-Hodgkin (1) · Venous Thromboembolism (1)
Neoplasms by Histologic Type (10) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphoproliferative Disorders (7) · Neoplasms (6) · Cardiovascular Diseases (4) · Lymphatic Diseases (4) · Vascular Diseases (4) · Blood Protein Disorders (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Paraproteinemias (3) · Disease Attributes (1)
Lenalidomide (3) · Trimethoprim, Sulfamethoxazole Drug Combination (3) · gamma-Globulins (3) · Amoxicillin-Potassium Clavulanate Combination (2) · Bortezomib (2) · Ciprofloxacin (2) · Dexamethasone (2) · Immunoglobulins, Intravenous (2) · Busulfan (1) · Doxorubicin (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Melphalan (1) · Stem Cell Transplantation (1) · Surveys and Questionnaires (1)
Monash University (4) · University Hospital, Toulouse (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · M.D. Anderson Cancer Center (1) · Poitiers University Hospital (1) · University Hospital, Grenoble (1)
Australia (4) · France (4) · Belgium (1) · Switzerland (1) · United States (1)
Zoe McQuilten, Professor (4) · Muzaffar H. Qazilbash, MD (1)
PMID 16404741, PMID 22571202, PMID 23194056, PMID 28379796, PMID 30859608, PMID 30910541, PMID 32090636, PMID 32687451, PMID 34643690, PMID 36828828, PMID 38023148, PMID 38830994
2005 (1), 2009 (1)